BROOKS · Healthcare · Drug Manufacturers - Specialty & Generic
| Share price | ₹67.70 |
| Market cap | ₹199 Cr |
| P/E ratio | 15.1 |
| P/B ratio | 1.6 |
| ROCE | 20.0% |
| Book value | ₹41.64 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹85 Cr | ₹25 Cr | 6.4% |
| 2025 | ₹82 Cr | ₹-10 Cr | 7.9% |
| 2024 | ₹79 Cr | ₹-20 Cr | 1.8% |
| 2023 | ₹62 Cr | ₹-21 Cr | -53.7% |
| 2022 | — | — | — |
Brooks Laboratories Limited operates as a pharmaceutical manufacturer in India and internationally. It operates in two segments, Manufacturing and Trading. The company offers liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; and B-Lactam and cephalosporin tablets, dry powder syrups, and injections. It is also involved in loan-licensing business relating to pharmaceutical products, ingredients, and intermediaries; and trading in pharmaceutical products, ingredients, and intermediaries. In addition, the company offers oncolog